1	PHARMACY PRACTICE ACT REVISIONS
2	2012 GENERAL SESSION
3	STATE OF UTAH
4	Chief Sponsor: Curtis S. Bramble
5	House Sponsor: Evan J. Vickers
6 7	LONG TITLE
8	General Description:
9	This bill amends the Pharmacy Practice Act to permit certain prescribing practitioners
\mathbf{C}	to dispense certain drugs without a license under the Pharmacy Practice Act, and makes
1	conforming amendments in the Utah Optometry Practice Act, the Nurse Practice Act,
2	the Utah Medical Practice Act, the Utah Osteopathic Medical Practice Act, and the
3	Physician Assistant Act.
1	Highlighted Provisions:
5	This bill:
ó	 requires a prescribing practitioner who will dispense a drug without being licensed
7	under the Pharmacy Practice Act to notify the Division of Occupational and
3	Professional Licensing of the practitioner's intent to dispense;
)	 requires the dispensing practitioner to follow purchasing and distribution
\mathbf{C}	requirements established by the division by administrative rule;
1	 defines cancer drug regimen;
2	 exempts an oncologist or medical personnel acting under the direction of an
3	oncologist from being licensed under the Pharmacy Practice Act to dispense a
4	cancer drug regimen to a patient who is undergoing chemotherapy in an outpatient



25

clinic setting;

26	• excludes Schedule I, II, and III drugs from the drugs an oncologist may dispense;
27	 makes it unprofessional conduct for a prescribing practitioner who dispenses a drug,
28	to dispense the drug in violation of the exemption in the Pharmacy Practice Act;
29	 directs the Division of Occupational and Professional Licensing to evaluate the
30	prescribing practitioner exemptions from licensing for dispensing drugs and to
31	report the findings of the evaluation to the Legislature; and
32	sunsets the exemption from licensure for oncologists in July 2015.
33	Money Appropriated in this Bill:
34	None
35	Other Special Clauses:
36	None
37	Utah Code Sections Affected:
38	AMENDS:
39	58-16a-502 , as last amended by Laws of Utah 2000, Chapter 160
40	58-17b-309, as last amended by Laws of Utah 2011, Chapter 76
40a	Ĥ→ 58-31b-502, as last amended by Laws of Utah 2006, Chapter 291 ←Ĥ
41	58-67-502 , as last amended by Laws of Utah 2011, Chapter 206
42	58-68-502 , as enacted by Laws of Utah 1996, Chapter 248
43	58-70a-502 , as enacted by Laws of Utah 1997, Chapter 229
44	63I-1-258, as last amended by Laws of Utah 2010, Chapter 188
45	ENACTS:
46	58-17b-309.5 , Utah Code Annotated 1953
47	
48	Be it enacted by the Legislature of the state of Utah:
49	Section 1. Section 58-16a-502 is amended to read:
50	58-16a-502. Unprofessional conduct.
51	"Unprofessional conduct" includes, in addition to the definition in Section 58-1-501:
52	(1) using or employing the services of an optometric assistant to assist a licensee in any
53	manner not in accordance with:
54	(a) the generally recognized practices and standards of ethics of the profession; or
55	(b) applicable state law or division rule;
56	(2) failure to refer a patient to an appropriate licensed practitioner when:

31	(a) the patient's condition does not respond to treatment; or
58	(b) the treatment is not within the scope of competence or licensure of the licensee;
59	(3) providing confidential information regarding a patient to any third party who does
60	not have a legal and professional ground for obtaining the information;
61	(4) knowingly prescribing, selling, giving away, or administering any prescription drug
62	[except] unless:
63	(a) for a legitimate medical purpose [and];
64	(b) upon a proper diagnosis indicating the use of the drug in the amount prescribed or
65	provided; and
66	(c) in compliance with Section 58-17b-309;
67	(5) giving or receiving directly or indirectly any fee, commission, rebate, or other
68	compensation for professional services not actually and personally rendered, except as part of a
69	legal relationship within a lawful professional partnership, corporation, or association;
70	(6) failure to transfer pertinent and necessary information from a patient's medical
71	records to another optometrist or physician when so requested by the patient or his
72	representative, as designated in writing; or
73	(7) failure to provide a contact lens prescription to a person who sells contact lenses in
74	accordance with Section 58-16a-306.
75	Section 2. Section 58-17b-309 is amended to read:
76	58-17b-309. Exemptions from licensure.
77	(1) For purposes of this section:
78	(a) "Cosmetic drug":
79	(i) means a prescription drug that is:
80	(A) for the purpose of promoting attractiveness or altering the appearance of an
81	individual; and
82	(B) listed as a cosmetic drug subject to the exemption under this section by the division
83	by administrative rule; and
84	(ii) does not include a prescription drug that is:
85	(A) a controlled substance;
86	(B) compounded by the physician; or
87	(C) prescribed or used for the patient for the purpose of diagnosing, curing, mitigating,

88	treating, or preventing a disease.
89	(b) "Injectable weight loss drug":
90	(i) means an injectable prescription drug:
91	(A) prescribed to promote weight loss; and
92	(B) listed as an injectable prescription drug subject to exemption under this section by
93	the division by administrative rule; and
94	(ii) does not include a prescription drug that is a controlled substance.
95	(c) "Prescribing practitioner" means an individual licensed under:
96	(i) Chapter 31b, Nurse Practice Act, as an advanced practice registered nurse with
97	prescriptive practice;
98	(ii) Chapter 67, Utah Medical Practice Act;
99	(iii) Chapter 68, Utah Osteopathic Medical Practice Act; or
100	(iv) Chapter 70a, Physician Assistant Act.
101	(2) In addition to the exemptions from licensure in [Section] Sections 58-1-307 and
102	58-17b-309.5, the following individuals may engage in the acts or practices described in this
103	section without being licensed under this chapter:
104	(a) if the individual is described in Subsections (2)(b), (d), and (e), the individual
105	notifies the division in writing of the individual's intent to dispense a drug under this
106	subsection;
107	[(a)] (b) a person selling or providing contact lenses in accordance with Section
108	58-16a-801;
109	[(b)] (c) an individual engaging in the practice of pharmacy technician under the direct
110	personal supervision of a pharmacist while making satisfactory progress in an approved
111	program as defined in division rule;
112	[(c)] (d) a prescribing practitioner who prescribes and dispenses a cosmetic drug or an
113	injectable weight loss drug to the prescribing practitioner's patient in accordance with
114	Subsection (4); [and] or
115	[(d)] (e) an optometrist, as defined in Section 58-16a-102, acting within the
116	optometrist's scope of practice as defined in Section 58-16a-601, who prescribes and dispenses
117	a cosmetic drug to the optometrist's patient in accordance with Subsection (4).
118	(3) In accordance with Subsection 58-1-303(1)(a), an individual exempt under

119	Subsection (2)[(b)](c) must take all examinations as required by division rule following	
120	completion of an approved curriculum of education, within the required time frame. This	
121	exemption expires immediately upon notification of a failing score of an examination, and the	
122	individual may not continue working as a pharmacy technician even under direct supervision.	
123	(4) A prescribing practitioner or optometrist is exempt from licensing under the	
124	provisions of this part if the prescribing practitioner or optometrist:	
125	(a) (i) writes a prescription for a drug the prescribing practitioner or optometrist has the	
126	authority to dispense under Subsection (4)(b); and	
127	(ii) informs the patient:	
128	(A) that the prescription may be filled at a pharmacy or dispensed in the prescribing	
129	practitioner's or optometrist's office;	
130	(B) of the directions for appropriate use of the drug;	
131	(C) of potential side-effects to the use of the drug; and	
132	(D) how to contact the prescribing practitioner or optometrist if the patient has	
133	questions or concerns regarding the drug;	
134	(b) dispenses a cosmetic drug or injectable weight loss drug only to the prescribing	
135	practitioner's patients or for an optometrist, dispenses a cosmetic drug only to the optometrist's	
136	patients; [and]	
137	(c) follows labeling, record keeping, patient counseling, [and] storage, purchasing and	
138	distribution, operating, treatment, and quality of care requirements established by	
139	administrative rule adopted by the division in consultation with the boards listed in Subsection	
140	(5)(a)[-]; and	
141	(d) follows USP-NF 797 standards for sterile compounding if the drug dispensed to	
142	patients is reconstituted or compounded.	
143	(5) (a) The division, in consultation with the board under this chapter, the Physician	
144	Licensing Board, the Osteopathic Physician Licensing Board, the Physician Assistant Licensing	
145	Board, the Board of Nursing, and the Optometrist Licensing Board shall adopt administrative	
146	rules pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act to designate:	
147	(i) the prescription drugs that may be dispensed as a cosmetic drug or weight loss drug	
148	under this section; and	
149	(ii) the requirements under Subsection (4)(c).	

150	(b) When making a determination under Subsection (1)(a), the division and boards
151	listed in Subsection (5)(a), may consider any federal Food and Drug Administration indications
152	or approval associated with a drug when adopting a rule to designate a prescription drug that
153	may be dispensed under this section.
154	(c) The division may inspect the office of a prescribing practitioner or optometrist who
155	is dispensing under the provisions of this section, in order to determine whether the prescribing
156	practitioner or optometrist is in compliance with the provisions of this section. If a prescribing
157	practitioner or optometrist chooses to dispense under the provisions of this section, the
158	prescribing practitioner or optometrist consents to the jurisdiction of the division to inspect the
159	prescribing practitioner's or optometrist's office and determine if the provisions of this section
160	are being met by the prescribing practitioner and optometrist.
161	(d) If a prescribing practitioner or optometrist violates a provision of this section, the
162	prescribing practitioner or optometrist may be subject to discipline under:
163	(i) this chapter; and
164	(ii) (A) Chapter 16a, Utah Optometry Practice Act;
165	(B) Chapter 31b, Nurse Practice Act;
166	(C) Chapter 67, Utah Medical Practice Act;
167	(D) Chapter 68, Utah Osteopathic Medical Practice Act; or
168	(E) Chapter 70a, Physician Assistant Act.
169	(6) Except as provided in Subsection (2)[(d)](e), this section does not restrict or limit
170	the scope of practice of an optometrist or optometric physician licensed under Chapter 16a,
171	Utah Optometry Practice Act.
172	Section 3. Section 58-17b-309.5 is enacted to read:
173	58-17b-309.5. Exemption for prescribing practitioner of cancer drug regimen
174	Division study of dispensing practitioners.
175	(1) For purposes of this section, "cancer drug treatment regimen":
176	(a) means a prescription drug used to treat cancer, manage its symptoms, or provide
177	continuity of care for a cancer patient;
178	(b) includes:
179	(i) a chemotherapy drug administered intravenously, orally, rectally, or by dermal
180	methods; and

181	(ii) a drug used to support cancer treatment, including to treat, alleviate, or minimize
182	physical and psychological symptoms or pain, or to improve patient tolerance of cancer
183	treatments or prepare a patient for a subsequent course of therapy; and
184	(c) does not mean a drug listed under federal law as a Schedule I, II, or III drug.
185	(2) In addition to the exemption from licensure under Section 58-1-307, the following
186	individuals are exempt from licensure under this chapter:
187	(a) an individual who:
188	(i) meets the requirements of Subsection (2)(b) or (c); and
189	(ii) notifies the division that the individual intends to dispense a cancer drug regimen
190	under this section;
191	(b) a prescribing practitioner who:
192	(i) treats a patient who is currently undergoing chemotherapy in an outpatient clinic
193	setting;
194	(ii) prescribes a cancer drug treatment regimen to the patient;
195	(iii) determines that providing the cancer drug treatment regimen to the patient in the
196	outpatient clinic setting is in the best interest of the patient, or provides better access to care for
197	the patient;
198	(iv) discloses to the patient that the cancer drug treatment regimen may be obtained
199	from a pharmacy unaffiliated with the prescribing practitioner and offers to the patient the
200	opportunity to consult with a pharmacist if the patient desires patient counseling;
201	(v) does not directly or indirectly mark up, charge a commission, or make a profit on
202	providing the cancer drug regimen, but may obtain payment for expenses and services related
203	to providing the cancer drug regimen;
204	(vi) provides the cancer drug treatment regimen to the patient, or directs another person
205	under Subsection (2)(c) to provide the cancer drug treatment regimen to the patient;
206	(vii) is certified or eligible to be certified by the American Board of Internal Medicine
207	in medical oncology;
208	(viii) reports to the Utah Controlled Substance Database in the same manner as
209	required by Section 58-37f-203, and follows labeling, recordkeeping, patient counseling,
210	purchasing and distribution, operating, treatment, quality of care, and storage requirements
211	established by administrative rule adopted by the division in consultation with the board; and

212	(ix) follows the USP-NF 797 standards for sterile compounding if the drug dispensed
213	to the patient is reconstituted or compounded; and
214	(c) a person who is not a prescribing practitioner who:
215	(i) is employed as a health care provider by a prescribing practitioner or the outpatient
216	clinic setting in which the prescribing practitioner works and is acting within the individual's
217	scope of practice;
218	(ii) is acting under the direction of a prescribing practitioner who is immediately
219	available on site for any necessary consultation, and who has complied with Subsection
220	<u>(2)(b)(i);</u>
221	(iii) prepares or provides the cancer drug treatment regimen to the patient at the
222	outpatient clinic setting; and
223	(iv) follows Subsections (2)(b)(iv), (v), and (viii).
224	(3) (a) The division shall work with stakeholders to evaluate the exemptions to
225	licensure under this title in Subsections 58-17b-309(2)(a), (c), and (d) and this section.
226	(b) The evaluation under this Subsection (3) shall include:
227	(i) practitioner compliance with the requirements of this section and Section
228	<u>58-17b-309;</u>
229	(ii) current research on dispensing and patient safety:
230	(iii) survey of other state dispensing laws; and
231	(iv) recommendations for future action concerning practitioner dispensing.
232	(c) The division shall report to the Legislature's Health and Human Services Interim
233	Committee by November 30, 2012, and by November 30, 2013, with the results and
234	recommendations from the evaluation required by this Subsection (3).
235	(4) This section sunsets in accordance with Section 63I-1-258.
235a	Ĥ→ Section 4. Section 58-31B-502 is amended to read:
235b	58-31b-502. Unprofessional conduct.
235c	"Unprofessional conduct" includes:
235d	(1) failure to safeguard a patient's right to privacy as to the patient's person, condition,
235e	diagnosis, personal effects, or any other matter about which the licensee is privileged to know because
235f	of the licensee's or person with a certification's position or practice as a nurse or practice as a
235g	medication aide certified;
235h	(2) failure to provide nursing service or service as a medication aide certified in a manner that
235i	demonstrates respect for the patient's human dignity and unique personal character and needs
235j	without regard to the patient's race, religion, ethnic background, socioeconomic status, age, sex, or the
235k 235l	nature of the patient's health problem; (3) engaging in sexual relations with a patient during any:
235m	(a) period when a generally recognized professional relationship exists between the person
235m	licensed or certified under this chapter and patient; or

235o (b) extended period when a patient has reasonable cause to believe a professional relationship exists between the person licensed or certified under the provisions of this chapter and the patient; 235p 235q (4) (a) as a result of any circumstance under Subsection (3), exploiting or using information 235r about a patient or exploiting the licensee's or the person with a certification's professional relationship between the licensee or holder of a certification under this chapter and the patient; or 235s 235t (b) exploiting the patient by use of the licensee's or person with a certification's knowledge of 235u the patient obtained while acting as a nurse or a medication aide certified; 235v (5) unlawfully obtaining, possessing, or using any prescription drug or illicit drug; 235w (6) unauthorized taking or personal use of nursing supplies from an employer; 235x (7) unauthorized taking or personal use of a patient's personal property; (8) knowingly entering into any medical record any false or misleading information or altering 235y 235z a medical record in any way for the purpose of concealing an act, omission, or record of events, 235aa medical condition, or any other circumstance related to the patient and the medical or nursing care 235ab provided; 235ac (9) unlawful or inappropriate delegation of nursing care; (10) failure to exercise appropriate supervision of persons providing patient care services 235ad 235ae under supervision of the licensed nurse; (11) employing or aiding and abetting the employment of an unqualified or unlicensed person 235af 235ag to practice as a nurse; 235ah (12) failure to file or record any medical report as required by law, impeding or obstructing the filing or recording of such a report, or inducing another to fail to file or record such a report: 235ai (13) breach of a statutory, common law, regulatory, or ethical requirement of confidentiality 235aj 235ak with respect to a person who is a patient, unless ordered by a court; (14) failure to pay a penalty imposed by the division; 235al (15) prescribing a schedule II-III controlled substance without a consulting physician or 235am 235an outside of a consultation and referral plan; [and] 235ao (16) violating Section 58-31b-801 [-]; and (17) violating the dispensing requirements of Section 58-17b-309 or Section 58-17b-309.5, if 235ap 235aq applicable. ←Ĥ Section $\hat{H} \rightarrow [4] 5 \leftarrow \hat{H}$. Section 58-67-502 is amended to read: 236 237 58-67-502. Unprofessional conduct. 238 "Unprofessional conduct" includes, in addition to the definition in Section 58-1-501[7]: 239 (1) using or employing the services of any individual to assist a licensee in any manner 240 not in accordance with the generally recognized practices, standards, or ethics of the 241 profession, state law, or division rule[, or]; 242 (2) making a material misrepresentation regarding the qualifications for licensure under

243	Section 58-67-302.7[.]; or	
244	(3) violating the dispensing requirements of Section 58-17b-309 or 58-17b-309.5 if	
245	applicable.	
246	Section 5. Section 58-68-502 is amended to read:	
247	58-68-502. Unprofessional conduct.	
248	"Unprofessional conduct" includes, in addition to the definition in Section 58-1-501[
249	(1) using or employing the services of any individual to assist a licensee in any manner	
250	not in accordance with the generally recognized practices, standards, or ethics of the	
251	profession, state law, or division rule[-]; or	
252	(2) violating the dispensing requirements of Section 58-17b-309 or 58-17b-309.5 if	
253	applicable.	
254	Section 6. Section 58-70a-502 is amended to read:	
255	58-70a-502. Unlawful conduct.	
256	"Unlawful conduct" includes:	
257	(1) engaging in practice as a licensed physician assistant while not under the	
258	supervision of a supervising physician or substitute supervising physician[-]; or	
259	(2) violating the drug dispensing requirements of Section 58-17b-309 or 58-17b-309.5	
260	if applicable.	
261	Section 7. Section 63I-1-258 is amended to read:	
262	63I-1-258. Repeal dates, Title 58.	
263	(1) Title 58, Chapter 9, Funeral Services Licensing Act, is repealed July 1, 2018.	
264	(2) Title 58, Chapter 13, Health Care Providers Immunity from Liability Act, is	
265	repealed July 1, 2016.	
266	(3) Title 58, Chapter 15, Health Facility Administrator Act, is repealed July 1, 2015.	
267	(4) Section 58-17b-309.5 is repealed July 1, 2015.	
268	[(4)] (5) Title 58, Chapter 20a, Environmental Health Scientist Act, is repealed July 1,	
269	2013.	
270	[(5)] (6) Title 58, Chapter 40, Recreational Therapy Practice Act, is repealed July 1,	
271	2013.	
272	[(6)] (7) Title 58, Chapter 41, Speech-language Pathology and Audiology Licensing	
273	Act, is repealed July 1, 2019.	

02-27-12 5:21 PM

6th Sub. (Cherry) S.B. 161

274	[(7)] (8) Title 58, Chapter 42a, Occupational Therapy Practice Act, is repealed	ed July 1,
275	2015.	
276	[(8)] (9) Title 58, Chapter 46a, Hearing Instrument Specialist Licensing Act,	is
277	repealed July 1, 2013.	
278	[(9)] (10) Title 58, Chapter 47b, Massage Therapy Practice Act, is repealed J	uly 1,
279	2014.	
280	[(10)] (11) Title 58, Chapter 72, Acupuncture Licensing Act, is repealed July	1, 2017.
281	[(11)] <u>(12)</u> Section 58-13-2.5 is repealed July 1, 2013.	